Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors
- 14 March 2017
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (8) , e375-e377
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialThe Lancet, 2015
- Granulomatous reaction to red tattoo pigment treated with allopurinolJournal of Cosmetic Dermatology, 2015
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- Myeloid‐derived suppressor cells in malignant melanomaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2014
- Cutaneous Granulomatous Eruption and Successful Response to Potent Topical Steroids in Patients Undergoing Targeted BRAF Inhibitor Treatment for Metastatic MelanomaJAMA Dermatology, 2014
- Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsInternational Journal of Cancer, 2013
- Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanomaOncoImmunology, 2012
- Granulomatous tattoo reaction in a patient treated with etanerceptJournal of the European Academy of Dermatology and Venereology, 2007